vs
Side-by-side financial comparison of Dime Community Bancshares, Inc. (DCOM) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Dime Community Bancshares, Inc. is the larger business by last-quarter revenue ($123.8M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, Dime Community Bancshares, Inc. posted the faster year-over-year revenue change (3040.1% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 22.9%).
The Dime Community Bank, originally known as the Dime Savings Bank of Williamsburgh, is a local, FDIC-insured bank headquartered in Hauppauge, New York. Founded in 1864, the bank was originally based in the Williamsburg neighborhood of Brooklyn, New York, and continues to operate with a strong market presence in this area. In 2017, Dime moved its headquarters to Brooklyn Heights. On Monday, February 1, 2021, Bridge Bancorp Inc. and Dime Community Bancshares successfully closed on a merger of ...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
DCOM vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $86.8M |
| Net Profit | — | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 38.6% | -84.7% |
| Net Margin | — | — |
| Revenue YoY | 3040.1% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.68 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $86.8M | ||
| Q3 25 | $115.6M | $67.5M | ||
| Q2 25 | $109.7M | $60.0M | ||
| Q1 25 | $103.8M | $49.3M | ||
| Q4 24 | $3.9M | $73.7M | ||
| Q3 24 | $87.6M | $58.6M | ||
| Q2 24 | $87.3M | $31.1M | ||
| Q1 24 | $82.0M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $27.7M | $-91.3M | ||
| Q2 25 | $29.7M | $-111.7M | ||
| Q1 25 | $21.5M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.3M | $-83.5M | ||
| Q2 24 | $18.5M | $-97.1M | ||
| Q1 24 | $17.7M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 38.6% | -84.7% | ||
| Q3 25 | 34.7% | -140.7% | ||
| Q2 25 | 36.6% | -189.8% | ||
| Q1 25 | 27.6% | -245.8% | ||
| Q4 24 | -433.6% | -117.5% | ||
| Q3 24 | 20.8% | -152.1% | ||
| Q2 24 | 29.8% | -327.6% | ||
| Q1 24 | 29.6% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | 23.9% | -135.3% | ||
| Q2 25 | 27.1% | -186.2% | ||
| Q1 25 | 20.7% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 15.2% | -142.7% | ||
| Q2 24 | 21.2% | -312.2% | ||
| Q1 24 | 21.6% | -15800.8% |
| Q4 25 | $0.68 | — | ||
| Q3 25 | $0.59 | — | ||
| Q2 25 | $0.64 | $-0.33 | ||
| Q1 25 | $0.45 | $-0.36 | ||
| Q4 24 | $-0.58 | $-0.24 | ||
| Q3 24 | $0.29 | $-0.28 | ||
| Q2 24 | $0.43 | $-0.34 | ||
| Q1 24 | $0.41 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $698.6M |
| Total Assets | $15.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $1.5B | $698.6M | ||
| Q3 25 | $1.5B | $702.3M | ||
| Q2 25 | $1.4B | $698.5M | ||
| Q1 25 | $1.4B | $767.9M | ||
| Q4 24 | $1.4B | $710.4M | ||
| Q3 24 | $1.3B | $773.5M | ||
| Q2 24 | $1.3B | $768.5M | ||
| Q1 24 | $1.2B | $680.0M |
| Q4 25 | $15.3B | $913.2M | ||
| Q3 25 | $14.5B | $904.9M | ||
| Q2 25 | $14.2B | $907.4M | ||
| Q1 25 | $14.1B | $966.7M | ||
| Q4 24 | $14.4B | $910.4M | ||
| Q3 24 | $13.7B | $991.1M | ||
| Q2 24 | $13.5B | $964.3M | ||
| Q1 24 | $13.5B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $186.6M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $186.6M | $-52.6M | ||
| Q3 25 | $52.1M | $-78.7M | ||
| Q2 25 | $23.1M | $-67.4M | ||
| Q1 25 | $65.4M | $-103.7M | ||
| Q4 24 | $99.1M | $-73.3M | ||
| Q3 24 | $-33.3M | $-59.0M | ||
| Q2 24 | $12.6M | $-98.4M | ||
| Q1 24 | $30.7M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $51.2M | $-89.5M | ||
| Q2 25 | $20.4M | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | $-34.1M | $-61.3M | ||
| Q2 24 | $9.2M | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | 44.3% | -132.7% | ||
| Q2 25 | 18.6% | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | -38.9% | -104.6% | ||
| Q2 24 | 10.5% | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | 0.7% | 16.1% | ||
| Q2 25 | 2.4% | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 0.9% | 3.9% | ||
| Q2 24 | 3.9% | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | 1.88× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 3.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.50× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 1.74× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DCOM
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
